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Abstract
Background. The optimal therapy for hepatocellular carcinoma (HCC) is transplantation. For all those patients not eligible
for transplantation (or on the waiting list) among the treatments of choice used more frequently in recent years are resection
(RES) and radiofrequency ablation (RFA). RFA is less efficacious for HCC ranging over 3 cm. The aim of this study was to
compare RFA to RES in a restricted cohort of patients with a single naive HCC ranging from 3 to 5 cm in size and without
end-stage liver disease. Patients and methods. A total of 102 patients who had never been treated before were enrolled. Those
patients whose HCC position would have required too much parenchymal loss at RES (central or close to main vascular
structures) were treated with RFA (n60), and the others underwent RES (n42). The two groups were similar for HCC
size and liver disease status. The outcome was considered in terms of overall survival (OS) and disease-free survival (DFS)
calculated by the KaplanMeier method. Differences among groups were validated by log-rank test. Results. The RES group
seemed to present a better long-term OS (91%, 57%, and 43% vs 96%, 53%, and 32% at 1, 3, and 5 years, respectively)
and DFS (74%, 35%, and 14% vs 68%, 18%, and 0%, respectively) but there was no statistical significance. Age, gender,
virus etiology, HCC size and a-fetoprotein levels did not correlate with survival. Patients with recurrence within the first
12 months after treatment showed a worse long-term survival (p0.011). Patients in Child-Pugh class B had poor
prognoses compared with those in class A (p0.047). Conclusion. Even if RES seemed to promise better long-term results,
in the medium term this difference had no statistical significance. Survival in this series was more closely related to the stage
of the underlying liver disease than to treatment (RES/RFA).
Introduction
The incidence of hepatocellular carcinoma (HCC) is
still rising, making it one of the most common
malignancies worldwide [1]. Up to now, surgical
resection (RES) has been considered the first choice
treatment [24]. Orthotopic liver transplantation
(OLT) guarantees the best long-term survival and
disease-free survival in selected patients because it
removes the tumor as well as the cirrhotic liver [57].
Nevertheless, the shortage of organs makes it possible
to treat only a small proportion of patients by OLT.
Improvements in imaging and technology have pro-
moted the development of percutaneous techniques
such as transcatheter arterial embolization (TACE),
percutaneous ethanol injection (PEI), percutaneous
acetic injection (PAI), cryo-ablation, and radiofre-
quency ablation (RFA). Some of these techniques are
currently less used (PAI, cryo-ablation) while TACE is
mainly employed for advanced HCC [8]. RFA appears
to be one of the most efficacious percutaneous techni-
ques for HCC ablation, thanks to its predictable area of
induced necrosis and percentage of induced necrotic
cells, checked at the histological examination [913].
In the recent past RFA was mainly reserved for patients
with compromised hepatic function, who were not
eligible for surgery. It was also reserved for patients
with smaller tumors, since percutaneous ablative
procedures were considered less efficacious for bigger
HCCs [14]. However, clinical trials have recently
demonstrated that RFA shows a similar long-term
outcome to resection in the treatment of small HCCs.
From the literature it is not clear how comparable the
two techniques are for larger HCCs (3 cm). The aim
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of this study was to compare the outcome of RFA and
RES in patients at first diagnosis of a single HCC,
ranging in size from 3 to 5 cm, and with similar liver
function (Child Pugh class A or B).
Materials and methods
Patients
From 1999 to 2006, 283 patients underwent RES and
548 underwent RFA for HCC at our institute. In this
retrospective study, only patients with a single nodule
ranging from 3 to 5 cm, with no previous treatment for
HCC, with absence of extrahepatic tumor, and as-
signed to Child-Pugh class A or B, were included. The
criteria for choosing RFA treatment for a Child-Pugh
A/B patient were: a localization of the tumor requiring
too much parenchymal loss at RES or patient’s refusal
of surgery. All patients where reviewed by a multi-
disciplinary team and treated within 1 month from
diagnosis. A cohort of 60 patients in the RFA group
and 42 in the RES group was collected. The groups
were similar in terms of median age (RES: 67 years,
range 2880 years; RFA: 68 years, range 4085 years),
grade of liver disease calculated as Child-Pugh score
(RES: 28 A and 14 B; RFA: 44 A and 16 B), and
median tumor size (RES: 40 mm, range 3050 mm;
RFA: 36.5 mm, range 3050 mm). Of the total cohort,
57 patients suffered from hepatitis C infection (HCV),
22 from hepatitis B infection (HBV), 14 from both
infections (HCVHBV), 1 from alcoholic liver disease
(ALD), 1 from HCVALD, 1 from primary sclerosing
cholangitis, and 6 patients had unknown etiology
(Table I). Both surgery and RFA were performed by
the same team of surgeons.
Diagnosis of HCC and staging
At ultrasound (US; Toshiba Sono Layer v sal 38b,
Aloka Pro Sound SSD 5500), all subjects in the study
population presented a single lesion ranging from 3 to
5 cm. In cases with evidence of cirrhosis with
a-fetoprotein (AFP)200 and/or typical CT or MRI
features (rapid contrast enhancement and rapid
washout) biopsy was not performed [15,16], although
in the early years of the study many biopsies had been
performed even in these patients. All biopsies were
US-guided with a 17 gauge needle from HS Medical
(Aprilia, Latina, Italy).
In patient selection only the preoperative imaging
staging was considered, disregarding postoperative
staging (usually more sensitive thanks to the oppor-
tunities for peritoneal inspection, palpation, and
intraoperative US), as this was available only for
patients in the RES group.
Surgery
All procedures were carried out by open surgery: 31
patients underwent an anatomic segmentectomy, 5 a
bisegmentectomy, 5 a wedge resection, and 1 a right
hepatectomy. Different techniques were employed to
perform the parenchymal transection (clamp-crush-
ing, bipolar coagulation, US dissection, or radio-
frequency precoagulation).
RFA
Patients were usually admitted the afternoon before the
day of the procedure. All procedures were percuta-
neous and US-guided. A platelet count ]40 000 and a
PT-INR51.4 were required in our unit at the time of
treatment. Only four cases were performed under
general anesthesia because of poor patient compliance;
all the others were treated under sedation and local
anesthesia in the presence of an anesthetist and with
continuous non-invasive hemodynamic monitoring.
Both subcostal and intercostal approaches were used;
the anti-Trendelenburg position was often required
and in the intercostal approach the operating table was
Table I. Patients’ clinicopathological characteristics.
Characteristic RFA (n60) Resection (n42) p value
Age (median and range) 68 (4285) 67 (2880) NS (0.595)%
Gender NS (0.977)
Male 47 33
Female 13 9
Etiology of cirrhosis
Hepatitis C virus 32 25 NS (0.534)
Hepatitis B virus 12 10 NS (0.645)
Hepatitis B and C virus 11 3 NS (0.066)$
Other causes 5 4 NS (0.266) $
Liver function (Child-Pugh score) NS (0.467)
Class A 44 28
Class B 16 14
AFP200 (ng/ml) 3 5 NS (0.201)$
Median tumor size (mm) 36.5 (3050) 40 (3050) NS (0.149) %
NS, not significant; AFP, a-fetoprotein.
x2, $Fisher’s exact test, %MannWhitney.
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slightly rotated towards the patient’s left side. A radio-
frequency generator from Radionics (Tyco, Burling-
ton, Massachusetts, USA; now Valleylab) was
employed; 31 patients were treated with a single cooled
needle (usually with multiple positioning), 29 patients
with a triple cooled needle. Bigger nodules often
required multiple insertions. In each insertion up to
200 W for 12 min were given, using the automatic
impedance-controlled modality. Needles were ex-
tracted at a temperature of ]858C. No antibiotic
prophylaxis was used.
Follow-up
All patients were followed up by three-phase CT scans
performed 40 days after treatment and then once
every 12 months. Blood tests (including AFP level,
bilirubin, albumin, PT-INR, and creatinine) and US
were repeated every 3 months. In cases of doubt at
US, a CT scan was performed. In cases of increased
AFP with negative US and CT a PET scan was
required. Intrahepatic HCC recurrence was consid-
ered as either residual vital tumor at the treated site
(unclear surgical margins, incomplete RFA treat-
ment) or at a distant site from the primary tumor.
Validation of treatment efficacy and statistical analysis
Categorical variables were compared with the x2 test;
continuous variables with MannWhitney; a p valueB
0.05 was considered statistically significant.
Overall survival (OS) was defined as the interval
between treatment and death or the most recent
follow-up visit. Disease-free survival (DSF) was
defined as the interval between treatment and the
date of diagnosis of recurrence.
The cumulative OS and DFS curves were plotted
by the KaplanMeier method. Comparisons between
subgroups by treatment, age, tumor size, Child-Pugh
class, etiology of background liver disease, serum AFP
level, and time of appearance of recurrence were made
by the log-rank test. A value of pB0.05 was con-
sidered statistically significant.
Complications were classified in five classes: 1, any
deviation from the normal postoperative course with-
out the need for drugs or intervention; 2, requiring
specific pharmacological treatment; 3, requiring sur-
gical or radiological intervention; 4, life-threatening
complications; 5, death [17].
Results
The mean9SD duration of follow-up was 27918.7
months in the RFA group and 31.3924.3 in the RES
group.
There was one in-hospital death in the RES group
(1/422.3%) from bleeding and liver failure after a
bisegmentectomy (left-lateral bisebmentectomy,
Child-Pugh class B). No death occurred in the RFA
group (Table II).
Two patients had a transient liver failure after RFA,
none after surgery. One patient developed metastasis
in the thoracic wall at the insertion site of the needle
after RFA. Complications are summarized and classi-
fied in Table III.
Median hospital stay in the RFA group was 2
(116) days, vs 5.5 (343) days in the RES group
(pB0.001).
At the follow-up CT scan, 40 days after treatment,
five patients (5.4%) in the RFA group showed
contrast enhancement at the treatment site, consid-
ered as incomplete necrosis of the HCC nodule; one
patient (2.7%) in the RES group showed residual
cancer on the surgical section plane.
Table II. Early outcome.
Parameter RFA Resection p value
Hospital mortality 0 1 NS (0.411)$
Complications 6 7 NS (0.987)
Median hospital stay 2 (116) 5.5 (343) B0.001%
x2, $Fisher’s exact test, %Mann-Whitney.
Table III. Complications for each method.
Grade Description RFA (n60) Resection (n42) p value
Grade 1 Wound infection 0 1 0.411
Grade 2 Urine infection 0 2 0.167
Liver failure 2 0 0.343
Grade 3 Hepatic abscess 1 0 0.588
Bilioma 0 1 0.411
Pleural effusion 2 1 0.432
Cutaneous metastasis 1 0 0.588
Grade 4 Renal failure 0 1 0.411
Grade 5 Intra-abdominal bleeding 0 1 0.411
Total 6 7 0.242
Fisher’s exact test was used.
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The 1-, 3- and 5-year OS in the RES group was
91%, 57%, and 43%, respectively, vs 96%, 53%, and
32% in the RFA group, with no statistical difference
between the two groups (p0.824) (Figure 1).
The 1-, 3- and 5-year DFS in the RES group was
74%, 35%, and 14%, respectively, vs 68%, 18%, and
0% in the RFA group, with no statistically significant
difference (p0.283) (Figure 2). The variables gen-
der, age, etiology, size of the nodule, and a-
fetoprotein20 were found to have no effect on OS
and DFS.
Patients in Child-Pugh class A showed a better
long-term OS (p0.0467) and a similar DFS (p
0.289) compared to those in class B (Figure 3).
Recurrence within the first year after treatment was
related to a worse OS (p0.011) (Figure 4).
Discussion
Surgical resection (RES) is usually still considered the
most effective treatment in patients with resectable
HCC and preserved liver function who are not eligible
for transplantation or are on the waiting list [27].
According the Barcelona Clinic Liver Cancer (BCLC)
strategy for staging and treatment, single small HCC
should be treated by RES and RFA should be
reserved only for multiple nodules (two or three) or
single nodules with increased portal pressure or
bilirubin levels [4,18]. Furthermore, RFA seemed to
be less effective for larger nodules (]3 cm) compared
with RES [18].
On these bases, in the past many institutes per-
formed RFA only in patients in worse conditions.
Thus, there is a mean bias when comparing results of
the outcome of RES and RFA.
To the authors’ knowledge there has been only one
randomized controlled trial comparing RES to RFA
[19]. Even if the present study is not randomized, the
results could be of some interest because of the
restricted inclusion criteria: the two groups (RFA/
RES) were similar for Child-Pugh class; the staging,
the treatment, and the follow-up were performed in the
same institution by the same team; all patients had a
single HCC at first diagnosis; and only medium-sized
HCC (35 cm) were included. The main difference
between the two groups is the tumor localization within
the liver, since in the RFA group HCCs were usually
situated centrally, and often closer to main vessels. This
could have a role when considering the outcomes
because it could be associated with a higher vascular
invasion, and consequently lead to a worse prognosis
for RFA patients [20].
The two populations were similarly matched for
the relevant prognostic factors such as number (n
1) and mean size of the nodes, Child-Pugh score,
AFP levels, and etiology of the underlying liver
disease.
Both treatments in this series were confirmed to be
safe, with only one death occurring in the RES group.
Also the complications rate was not different between
RES and RFA and was similar to the rates reported by
other authors [1922]. Important prognostic factors
were confirmed to be the grade of the underlying liver
disease (Child-Pugh class, p0.047) and the time to
recurrence (p0.011). Even if there was a trend
towards a worse DFS after RFA compared with RES,
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Figure 1. Overall survival:surgical resection (RES) vs radiofre-
quency ablation (RFA).
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Figure 2. Disease-free survival: surgical resection (RES) vs radio-
frequency ablation (RFA).
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Figure 3. Child- Pugh class: A vs B.
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Figure 4. Patients with early (E) (within first year) vs late (L)
recurrence: overall survival.
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and even if the 5-year survival was also lower in the
RFA group (32% vs 43%), there was no statistically
significant difference. Comparing data from the pre-
sent study to those from five other studies on the same
topic [19,2326] (Table IV), the following observa-
tions could be made. All papers come from two
distinct geographical areas: Italy and the south-east
of Asia. Absolute values in terms of OS and DFS are
better for patients from Asia. This difference could be
explained because patients enrolled in studies from
Asia are younger and have better hepatic function,
since all are in Child-Pugh class A, indirectly con-
firming that liver function is one of the most im-
portant prognostic factors. The shapes of the OS and
DFS curves are similar in most of the studies,
confirming a tendency to a better long-term survival
after RES. Nevertheless, a statistically significant
difference in OS was found in only one paper [23],
but in this paper there was a major selection bias since
patients enrolled in the RFA group had more nodules
(p0.0001) and a worse Child-Pugh class (p
0.0001). In all other comparative studies on this topic
[19,2426], and in the present one, no statistical
difference in OS was found between RES and RFA.
Perhaps by prolonging the follow-up of the studies
this difference might become evident. Perhaps a
difference in DFS, that was actually found only in
two comparative studies, could be even more evident
[23,26]. At present it seems reasonable to conclude
that RFA guarantees nearly similar medium-term OS
when compared to RES in patients suffering from a
35 cm single HCC, but at a lower cost (shorter
hospital stay) and less invasiveness for patients.
Patients affected by HCC will undergo several treat-
ments during their lives because of a recurrence rate
exceeding 70% in 5 years [2730]; for this reason
minimally invasive procedures such as RFA are
desirable. Actually, there is also an increasing ten-
dency towards using combinations of therapies (e.g.
chemoembolization, portal vein embolization, percu-
taneous ablation, radiotherapy, etc), as treatment or
as neoadjuvant therapies followed by surgical resec-
tion, showing promising results [31,32].
Survival with HCC seems to be most strictly
related to the underlying liver disease [33]. This is the
main reason for assessing whether there is still a real
advantage of surgical resection over less invasive treat-
ments, which may be true only for selected patients.
Table IV. Comparative studies (RES vs RFA) for HCCB5 cm.
Author
Setting
units Treatment
No. of
patients
Mean
age
Child-Pugh
class A/B
No. of
nodes
1/ 1
Node
size range
(cm)
Mean
follow-up
% 1,
3-years
OS
% 1,
3-years
DFS
Difference
OS
(p value)
Differ-
ence DFS
(p value)
Vivarelli
et al.
2004
[23]
2 RES 79 65 70/9* 66/13*  28.9 83, 65 79, 50
Italy RFA 79 67 43/36* 46/36*  15.6 78, 33 60, 20 0.002* 0.001*
Cho et al.
2005
[24]
1 RES 61 57 61/0  B5 21.9 98, 77 71, 36
Korea RFA 99 58 98/0  B5 23 95, 80 36, 30 0.77 0.65
Hong et al.
2005
[25]
1 RES 93 49* 93/0 93/0 B4 25.5% 97,.83 75, 54
Korea RFA 55 59* 55/0 55/0 B4 22.7% 100, 72 74, 40 0.24 054
Montorsi
et al.
2005
[26]
1 RES 40 67 36/4 40/0 B5 22.4 84, 73 84, 59
Italy RFA$ 58 67 40/18 58/0 B5 25.7 85, 61 67, 32 0.139 0.024*
Chen MS
& coll.
2006
[19]
(RCT)
1 RES 71 49.4 71/0 71/0 55 29.2 93, 73 86, 69
China RFA 90 51.9 90/0 90/0 55 27.9 95, 71 85, 64 0.05 0.05
Present
study
2007
1 RES 42 67 28/14 42/0 3]5 31.3 91, 57 74, 35
Italy RFA 60 68 44/16 60/0 3]5 27 96, 53 68, 18 0.824 0.283
RES, resection; RFA, radiofrequency ablation; RCT, randomized controlled trial; OS, overall survival; DFS, disease-free survival.
*Statistical significance (pB0.05).
$Laparoscopic RFA.
%Median.
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